首页> 外文期刊>American Journal of Clinical Oncology: Cancer Clinical Trials >Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
【24h】

Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.

机译:晚期卵巢癌患者血清中CA125和Bcl-2的统计学解释。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The present study was conducted to investigate the sensitivity, specificity, predictive values and accuracy of serum CA125 and Bcl-2 levels and their combination in advanced epithelial ovarian cancer patients. METHODS: Healthy controls (n = 117) with no gynecologic problems and patients with ovarian carcinoma (n = 117), pathologically verified, consecutively admitted to the Istanbul University, Oncology Institute during a one-year period were investigated. Serum Bcl-2 and CA125 were determined by using enzyme linked immunosorbent assay method. RESULTS: The serum bcl-2 and CA125 levels were significantly higher in patients with ovarian cancer than in the control group (P < 0.001). The diagnostic sensitivity and specificity, predictive values and accuracies were calculated for each marker and their combination. CONCLUSION: The best result was achieved with the combination of CA125-bcl-2. This combination fulfills the need of diagnosis of ovarian carcinoma for the best sensitivity and specificity.
机译:目的:本研究旨在研究晚期上皮性卵巢癌患者血清CA125和Bcl-2水平及其组合的敏感性,特异性,预测值和准确性。方法:对没有妇科问题的健康对照(n = 117)和经病理学验证并在一年期间连续入学伊斯坦布尔大学肿瘤研究所的卵巢癌患者(n = 117)进行了研究。血清Bcl-2和CA125采用酶联免疫吸附法测定。结果:卵巢癌患者的血清bcl-2和CA125水平显着高于对照组(P <0.001)。计算每种标记物及其组合的诊断敏感性和特异性,预测值和准确性。结论:CA125-bcl-2联合使用可获得最佳效果。这种组合满足诊断卵巢癌的最佳敏感性和特异性的需要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号